Novavax, Inc. NVV1.F · Stock Open Novavax, Inc. in new tab
Novavax, Inc. Analysis (NVV1.F)
Is Novavax, Inc. a good investment? Novavax, Inc. (NVV1.F) is currently trading at 11.46 EUR.
Earnings Schedule: Novavax, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is 32.30.
Investor FAQ
Does Novavax, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Novavax, Inc.?
Novavax, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -1.35.
Company Profile
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Split Date | Split Ratio to 1 |
|---|---|
| May 10, 2019 | 1:20 |
Community Discussion